This annual conference includes presentations on each of the four principal technologies of inhaled drug delivery – dry powder inhalers, metered dose inhalers, nebulizers and liquid inhalers. It will also cover the future European and UK regulatory processes following Brexit, which will be critical when developing product approval strategies in the future.
There are a number of key areas that are currently evolving and the latest thinking and progress on these will also be presented, including Human factor design and sensing/connecting technologies. These key evolving areas are subject to much debate and require careful consideration whilst developing an inhaled drug product.
Please note that this programme relates to the 2017 event. The new programme and brochure will be available shortly.
Please revisit this page in a few weeks time to see the programme for 2018.
*Exhibition stands are available at this meeting, for further information please click here
*Our media partner*
Programme Day One
09.30 Chairman’s welcome and Introduction
Dr Steve Nichols, Director, OINDP Consultancy, UK
09.40 Future needs for inhaled drug delivery
- What are unmet needs and drivers for change in inhaled delivery systems?
- How do the delivery systems in common use stack up against unmet needs and change drivers?
- What are some alternative approaches one might take to enhance a delivery system or develop a new delivery system?
Dr Paul Johnson, Senior Director of Inhaled Product Platforms, GSK, UK
10.20 Innovation in nebulized therapy
- Nebulized therapy is growing faster than other inhaled dosage forms, albeit from a smaller base
- There are significant unmet medical needs for patients that would benefit from nebulised therapy, which will be reviewed
- There are potential commercial advantages to develop nebulized therapies ahead of the corresponding inhaler
- The use of electronics facilitates the introduction of patient management solutions
Dr John Pritchard, Director PMO and Technology, Respiratory Drug Delivery, Sleep & Respiratory Care, Philips Healthcare, UK
11.30 Nebulizers – modern advances
Jason Cheng, CEO and Founder, HCmed Innovations
- New vibrating mesh technology
- Deepro HCM-860
Irene Wu, Operations Director, HCMed Innovations, The Netherlands
12.10 Functional respiratory imaging: how does it help to optimise drug delivery in the lung
- What is Functional Respiratory Imaging (FRI)
- Relation of FRI to APSD methods and scintigraphy
- FRI as a translational tool
Dr Wim Vos, Co-Founder, FLUIDDA, Belgium
14.10 Developing triple combination inhalers – the challenges
Francesca Usberti, Head of Respiratory Technical Leadership, CMC R&D, Chiesi, UK
14.50 Development of propellant free MDIs
- AeroMist non pressurized metered dose inhaler
- Human factors considerations for a new technology in an existing look and feel
Wilbur de Kruijf, Business Development, Medspray, Netherlands
16.10 The ADI – low velocity aqueous spray device
Tomas Norling, Director Inhalation R&D, Xellia Pharmaceuticals ApS, Denmark
16.50 The feasibility of aerosol-mediated delivery of next generation drugs: vaccines and cell-based therapies
- Overview of next generation drugs
- Rationale for pulmonary targeting of vaccines
- Review of existing vaccine/device combinations
- Requirements for optimal vaccine delivery
- Rationale for cell therapy targeted to the lung
- Review of existing cell therapy/device combinations
- Requirements for optimal cell therapy delivery
- Summary and Q&A
Dr Ronan MacLoughlin, Head of Science, Aerogen, Ireland
17.45 End of day one
17.45-18.45 NETWORKING DRINKS
Programme Day Two
09.15 Review of day one
Mike Holroyd, Senior Director, Mylan, UK
09.30 The UK regulatory future – the way forward after Brexit
- What are the key issues for the pharmaceutical industry for UK and EU 27
- What have we learnt so far and what are the next stages of the negotiations
- Preparations for March 2019
- What should we expect from March 2019
Dr David Jefferys, Senior Vice President, Global Regulatory, Eisai Europe, UK
10.10 Human factor regulations
- Human factors studies – a hype or a real need?
- Which guidelines cover human factors for pharmaceutical products? What do the guidelines say?
- Questions and problems
Dr Stefan Leiner, CMC Expert, Quality and Records Management, Boehringer Ingelheim Pharma GmbH and Co. KGm, Germany
11.30 How the demands of engineered particles are impacting filling technology…
- The trend towards engineered particles, including spray-dried powders, is changing the game with regard to development, clinical manufacturing and industrialisation of new formulations and devices
- We explore the key challenges and what they mean for lab, clinical and commercial manufacturing
Alex Jezequel, Projects Director, 3P Innovation, UK
12.10 Connected Asthma
- Connected drug delivery devices are here now, and will be a part of the future, but they are not a panacea
- This presentation will cover important questions such as: which disease indications, patient groups and devices are they appropriate for?
- How does connectivity affect device development?
- Who pays and who owns the data?
- How effective can we expect connectivity to be?
Tom Oakley, Director of Drug Delivery Device Development, Springboard
14.10 MDIs getting connected – Inspair sensor converts any device into a connected device
- The proper use of the device is one of the major issues in the respiratory field, specifically for PMDIs
- Inspair, a smart sensor compatible with all PMDIs, can record critical information: the pressure on the canister and the inhalation
- Inspair is a treatment monitoring solution designed to help patients follow the instructions for use of the device, educate them on the importance of the inhalation technique, and guarantee medication is properly delivered
- Highly customisable solution, can even be adapted for some DPIs
- Easy to industrialise for pharma, easy to adopt for patients
Arnaud Guillet, Business Development, Biocorp, France
14.50 *Smart inhalers – Improving adherence and reducing healthcare costs
- Global health data confirms that poor patient adherence to long-term therapies, such as asthma and COPD, contribute significantly to rising healthcare cost
- Smart Inhalers are emerging which enable more effective monitory of patient compliance and adherence, including remotely
- Clinical studies using smart devices have demonstrated improvements and translate directly to a reduction in healthcare cost
- Smart Inhalers face numerous challenges, from a wide range of stakeholder, for successful adoption on a global scale
Dana Shears, Director, Future Market Development, H&T Presspart, USA
15.30 3M Intelligent Control Inhaler
Sam Van Alstyne, New Products Marketing Manager, 3M Drug Delivery, USA
16.20 Chairmen’s closing remarks
16.30 End of conference and refreshments